PubblicazioniPublications    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   HomePubblicazioni
Pubblicazioni IGM

Effect of MRJF4 on C6 Glioma Cells Proliferation and Migration.

Autori

Pacella S, Fiorito J, Cacciatore I, di Giacomo V, Patruno A, Rapino M, Di Stefano A, Marinelli L, Fornasari E, Cataldi A, Prezzavento O, Marrazzo A.

Riferimenti

CENTRAL NERVOUS SYSTEM AGENTS IN MEDICINAL CHEMISTRY 17(2) 129-134, 2016

Autori CNR

RAPINO

Moduli

Abstract

BACKGROUND: MRJF4, a novel haloperidol metabolite II prodrug, was obtained through the esterification of the secondary hydroxyl group of haloperidol metabolite II with 4-phenylbutyric acid. The activities of (+/-)-MRJF4 and its two enantiomers [(+)-MRJF4 and (-)-MRJF4] as tumor specific inducers of pro-apoptotic genes were evaluated on malignant C6 glioma cells. In particular, changes in Nf-kB signaling pathway, activity of nitric oxide synthases (NOS), metalloproteinases (MMPs), and membrane adhesion proteins were investigated. RESULTS: IkB_ reduced phosphorylation and iNOS lowered activity could be correlated with the previously demonstrated decreased proliferation and tumor progression of C6 cells upon 24 h of treatment with all the three compounds. Integrin beta1 decreased expression, at the same experimental time, seems to support lower C6 cells migrative capability and the consequent reduced invasiveness of these cells upon treatment with (+/-)-MRJF4 and its enantiomers. CONCLUSIONS: These results suggest that this multi-target prodrug and its two enantiomers might be a valuable clinical tool for the treatment of metastatic glioblastoma.

Link all articolo

http://www.eurekaselect.com/145013/article

Parole Chiave

Note

10.2174/1871524916666160823122712

Indietro


Copyright © 2014 Home